Stack of report paper documents for business desk, Business papers for Annual Reports files. Business offices concept.

11/06/2026

European Court of Justice confirms STOT RE 2 Classification of Silanamine

  • European Court of Justice confirms the classification of silanamine as STOT RE 2

  • Read-across remains an accepted method for hazard assessment in CLH procedures

  • Ruling provides legal certainty and makes future regulatory assessments more predictable

Essen, Germany. The European Court of Justice (ECJ) has upheld the classification of silanamine in the hazard class STOT RE 2. Evonik takes note of the decision and welcomes the clarification it provides regarding assessment methodologies used in the harmonized classification and labeling (CLH) of chemicals.

The Court notably confirmed how the read-across approach is a permissible method for hazard assessment. This methodology is based on the assumption that similar substances exhibit similar toxicological properties and that certain test data generated for one substance may be used to assess another. Consequently, the ECJ judgment is expected to have broader significance for future substance classifications.

The case originated from Evonik's appeal to the ECJ after the General Court of the European Union (GC) had dismissed the company's action against the classification of silanamine as STOT RE 2. Silanamine is a hydrophobic, surface-treated synthetic amorphous silica (SAS).

The dispute centered on the interpretation and application of the CLP Regulation. In particular, Evonik challenged two aspects of the hazard assessment: the treatment of particle size characteristics as intrinsic properties of a substance and the acceptability of the read-across methodology. Evonik argued that the assessment was not based on inhalation studies performed with silanamine itself, but rather on test results obtained for other surface-modified silicas. The ECJ has now confirmed how a hazard assessment may be based on data from structurally or physicochemically comparable particulate substances. 

The judgment has immediate implications for the harmonized classification of silanamine as STOT RE 2 (specific target organ toxicity following repeated inhalation exposure, affecting the lungs).

"Beyond its implications for silanamine, we welcome the legal certainty provided by the judgment. Greater clarity regarding the application of read-across in CLH proceedings may contribute to more predictable regulatory assessments of modified synthetic amorphous silicas and other particulate substances in the future," says Frank Menzel, Vice President Regulatory Marketing Silica at Evonik Smart Effects business line.

Evonik: Leading beyond chemistry

Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €14.1 billion and earnings (adjusted EBITDA) of €1.9 billion in 2025. The common motivation of the approximately 31,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day.

About Advanced Technologies

The Advanced Technologies segment includes Evonik’s market-leading businesses that leverage technological expertise and process know-how. These businesses feature high-performance polymers and crosslinking agents, hydrogen peroxide and silica, as well as feed ingredients. In 2025, the segment generated sales of €5.9 billion with around 9,200 employees.

Disclaimer

In so far as forecasts or expectations are expressed in this release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.